Endoscopic Retrograde Cholangiopancreatography Market

Rising application of ERCP is driving the market growth

ERCP, also known as endoscopic retrograde cholangiopancreatography, is a method for identifying and treating problems with the pancreas, liver, gallbladder, and bile ducts. Endoscopic retrograde cholangiopancreatography (ERCP) is a procedure for diagnosing and treating pancreatobiliary diseases that combines luminal endoscopy with imaging based on fluoroscopy. It combines the use of an endoscope, a protracted, bendable, and illuminated tube, and X-ray technology. Undiagnosed stomach pain or jaundice, which causes the skin and eyes to turn yellow, may be the result of something that can be found out using ERCP.

If there is pancreatitis or liver, pancreas, or bile duct cancer, it can be used to learn more about such conditions. Endoscopic retrograde cholangiopancreatography (ERCP) can also detect diseases including bile duct obstructions or stones, as well as liquid discharge from the bile or pancreatic ducts. Other disorders that might be found with an ERCP include tumours, obstructions or limitations of the pancreatic ducts, and pollution in the bile ducts. Consequently, the market CAGR for endoscopic retrograde cholangiopancreatography is expanding.

Various organs of the digestive system, including the liver, pancreas, and gallbladder, are affected by gastrointestinal (Gl) illnesses. Gl diseases are a major contributor to worldwide morbidity and mortality and have a profound impact on millions of people. For instance, the 2019 International Foundation for Gastrointestinal Disorders Report states that GED affects roughly one-third of the population and is a major cause of bleeding issues, which is what is driving the expansion of the  market. The National Institutes of Health invested up to $1.6 billion in Gl research in 2017; Gl diseases impact 60–70 million Americans annually.

Primary biliary cholangitis (PBC) incidence, on the other hand, ranges from 5.8 to 15 cases per million people. The governments' attention has been called by a significant increase in the fatality rate, and as a result, the demand for treatment is expected to rise over the predicted period.

The usage of endoscopic equipment in the field of ERCP has increased in tandem with a quicker rate of population ageing worldwide. Visual impairment is occurring more frequently now than it ever has before due to population ageing. Comorbidities such as adenomas, hemangiomas, focal nodular hyperplasia (FNH), and pancreatic cancer have so been noted. The fourth most prevalent type of cancer in the world, pancreatic cancer, is what kills people the most. In the United States, 68.5% of pancreatic cancer diagnoses are made in people over 65, according to the National Cancer Database.

The number of old people with gastrointestinal and chronic biliary problems, as well as benign liver and pancreatic tumors, will rise as the elderly population rises. Thus, driving the endoscopic retrograde cholangiopancreatography market revenue.

The Global Endoscopic Retrograde Cholangiopancreatography Market Industry is also witnessing growth due to increased awareness and education regarding biliary disorders. Healthcare campaigns aimed at educating both patients and providers about the symptoms and treatment options for biliary diseases are becoming more prevalent. This heightened awareness is likely to lead to earlier diagnosis and treatment, thereby increasing the demand for ERCP procedures. As more individuals understand the benefits of timely intervention, the market is expected to expand significantly, aligning with the overall trends in healthcare education and patient engagement.

Rising healthcare expenditure across various regions is significantly impacting the Global Endoscopic Retrograde Cholangiopancreatography Market Industry. Governments and private sectors are investing more in healthcare infrastructure, which includes advanced diagnostic and therapeutic technologies. This increase in funding allows for the procurement of state-of-the-art endoscopic equipment and training for healthcare professionals. As a result, the market is poised for substantial growth, with projections indicating a rise to 6.39 USD Billion by 2035. Enhanced access to healthcare services, particularly in developing nations, further supports the expansion of ERCP procedures.

Technological innovations play a crucial role in the expansion of the Global Endoscopic Retrograde Cholangiopancreatography Market Industry. The introduction of advanced imaging techniques, such as high-definition endoscopy and digital enhancements, has improved the accuracy and safety of ERCP procedures. These advancements not only facilitate better visualization of the biliary tree but also enhance the overall patient experience. As a result, healthcare providers are increasingly adopting these technologies, contributing to a projected market growth to 6.39 USD Billion by 2035. The integration of artificial intelligence in diagnostic processes further indicates a promising future for ERCP.

The Global Endoscopic Retrograde Cholangiopancreatography Market Industry is experiencing growth due to the increasing prevalence of biliary disorders such as cholangitis and choledocholithiasis. As healthcare systems worldwide report a rise in these conditions, the demand for effective diagnostic and therapeutic procedures is escalating. In 2024, the market is projected to reach 2.28 USD Billion, reflecting the urgent need for advanced endoscopic techniques. This trend is likely to continue, as the World Health Organization indicates that biliary diseases are becoming more common, particularly in aging populations, thereby driving the adoption of ERCP procedures.

The Global Endoscopic Retrograde Cholangiopancreatography Market Industry is benefiting from a shift towards minimally invasive surgical techniques. Patients and healthcare providers alike are increasingly favoring procedures that reduce recovery time and minimize complications. ERCP, being a less invasive option for diagnosing and treating biliary and pancreatic disorders, aligns well with this trend. As the global healthcare landscape evolves, the demand for such procedures is expected to rise, contributing to a compound annual growth rate of 9.82% from 2025 to 2035. This shift not only enhances patient outcomes but also reduces the overall burden on healthcare systems.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American endoscopic retrograde cholangiopancreatography market area will dominate this market. This region is expanding as a result of intensive diagnostic imaging research and the rapid introduction of technologically advanced ERCP tools like sphincterotomes. The expansion of government healthcare funding and the presence of important companies like Hobbs Medical Inc. in the area are both contributing to the growth.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2  ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe endoscopic retrograde cholangiopancreatography market accounts for the second-largest market share due to the enormous negative impact biliary and pancreatic problems have on people's general health. These illnesses include Crohn's disease, inflammatory bowel disease, liver disease, pancreatitis, and gastroesophageal reflux disease (GERD). When the diseases have not been discovered in their earliest stages, surgical intervention is necessary to treat these problems in severe cases.  Further, the German endoscopic retrograde cholangiopancreatography market held the largest market share, and the UK endoscopic retrograde cholangiopancreatography market was the fastest growing market in the European region.

The Asia-Pacific Endoscopic retrograde cholangiopancreatography Market is expected to grow at the fastest CAGR from 2023 to 2032. The expansion of the healthcare industry is responsible for this growth. The growth of the Endoscopic Retrograde Cholangiopancreatography Market in the Asia-Pacific region is also being fueled by the rising awareness of the use of spincterotomes in the treatment of pancreatic and liver disorders. Moreover, China’s endoscopic retrograde cholangiopancreatography market held the largest market share, and the Indian endoscopic retrograde cholangiopancreatography market was the fastest growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the endoscopic retrograde cholangiopancreatography market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, endoscopic retrograde cholangiopancreatography industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the endoscopic retrograde cholangiopancreatography industry to benefit clients and increase the market sector. In recent years, the endoscopic retrograde cholangiopancreatography industry has offered some of the most significant advantages to market.

Major players in the endoscopic retrograde cholangiopancreatography market attempting to increase market demand by investing in research and development operations include Olympus Corporation (Japan), Fujifilm Holdings, Corporation (Japan), STERIS PLC (UK), Cook Medical (US), Boston Scientific Corporation (US), CONMED Corporation (US), HOYA Group (Japan), Q3 Medical Devices Limited (Ireland), Ambu Inc. (Denmark), Medtronic Plc (Ireland), and Others.

A corporation called Olympus Corp (Olympus) manufactures precise equipment and tools for optical and digital technologies. The company designs, manufactures, and distributes equipment and devices for the healthcare, information, medical, imaging, and other industrial industries. It offers medical systems like endotherapy devices, endoscopes, and endoscopy supplies to aid medical professionals in treating patients, as well as scientific solutions like laser scanning microscopes, remote visual inspection products, industrial and biological microscope systems, and non-destructive testing systems. In February 2020, the FDA has given Olympus' TJF-Q190V duodenoscope approval.

The product provides an antiseptic and disposable distal endcap made to reduce contamination and improve machine reprocessing.

ConMed Corp (ConMed) is a producer and distributor of surgical tools and instruments for minimally invasive treatments and monitoring. Arthroscopes, bronchoscopy tools, reconstructive systems, endoscopic ligator kits, trocars, balloons for stone removal, graspers, and scissors, suction irrigation tools, thermal tissue fusion systems, electrosurgical generators, pencil sheaths, smoke evacuation pencils, saws, and blades, endo mechanical instrumentation, and surgical visualization tools are some of the company's main products.